DoD Rare Cancers, Idea Development Award | W81XWH 22 RCRP IDA

Opportunity Information: Apply for W81XWH 22 RCRP IDA

The DoD Rare Cancers Research Program (RCRP) Idea Development Award (FY22) is a funding opportunity from the Department of Defense (USAMRAA) designed to push forward early-stage but promising research ideas aimed at reducing deaths and suffering caused by rare cancers. It is meant for projects that are still developing and not yet fully proven, but that have a credible path to generating influential data and opening up new directions for the field. The central goal is to accelerate progress toward meaningful breakthroughs, especially work that could change how rare cancers are understood, studied, or ultimately treated.

A defining feature of this award is its emphasis on conceptually innovative, high-risk/high-reward science. The program is looking for research that does more than add a small improvement to what is already known. Competitive applications are expected to propose something that genuinely shifts thinking: introducing a new paradigm, challenging an existing one, applying a fresh perspective to a long-standing problem, or using creative approaches in the research question, experimental strategy, technology, or adaptation of existing methods. Proposals that are expected to produce only incremental advances are specifically discouraged under the innovation criterion.

Impact is the other major driver. The funded work should have a strong potential to produce major advances that could noticeably improve outcomes for people affected by rare cancers. This does not necessarily mean the project must deliver an immediate clinical product, but it should be clearly positioned to generate findings that could substantially influence future research, enable new therapeutic approaches, strengthen biological understanding, or otherwise move the field forward in a way that matters for patients.

Applications must be built around a well-formulated, testable hypothesis supported by strong scientific rationale. While the award is intended for ideas in earlier development, it still requires preliminary data to demonstrate feasibility and to support the proposed hypothesis and research approach. Importantly, the preliminary evidence does not have to come directly from the specific rare cancer type or subtype being proposed. Data from related cancer contexts or other relevant systems can be acceptable, as long as the application provides a clear disease-specific rationale connecting that evidence to the rare cancer focus. The opportunity also notes that correlative studies tied to ongoing clinical research may be used as part of the supporting rationale.

From an administrative standpoint, the opportunity is listed as discretionary funding and may be made as a grant or cooperative agreement under CFDA 12.420. Eligibility is described as unrestricted, meaning it is broadly open to many entity types, subject to any additional eligibility clarifications in the full announcement. The funding opportunity number is W81XWH-22-RCRP-IDA. The posting date is April 20, 2022, with an original closing date of September 30, 2022. The opportunity anticipates making around 15 awards. The published award ceiling is listed as 0, which typically signals that applicants must rely on the full solicitation details for budget constraints or that a fixed ceiling is not stated in the summary field.

Overall, this award is best viewed as a mechanism for launching bold, well-justified rare cancer projects that have enough preliminary support to be believable, but that are daring enough to potentially produce outsized gains in knowledge and future patient benefit.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Rare Cancers, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 20, 2022.
• Applicants must submit their applications by Sep 30, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 15 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 RCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: